Guided Therapeutics (GTHP) FCF Margin (2011 - 2025)

Guided Therapeutics has disclosed FCF Margin across 15 years of filings, most recently posting 49.32% for Q4 2025.

• In Q4 2025, FCF Margin rose 3315068.0% year-over-year to 49.32%; the TTM figure through Jun 2026 stood at 231.38% (up 87455.0% YoY), while the FY2025 annual figure was 139.5%, up 1584621.0% from the prior year.
• FCF Margin came in at 49.32% for Q4 2025 at Guided Therapeutics, up from 461.67% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 208.33% in Q4 2021 to a low of 34650.0% in Q2 2021.
• Average FCF Margin over 5 years is 7831.92%, with a median of 1967.42% recorded in 2023.
• Year-over-year, FCF Margin sank 3215000 bps in 2024 and soared 3315068 bps in 2025.
• Over 5 years, FCF Margin stood at 208.33% in 2021, then slumped by 9844 bps to 20300.0% in 2022, then jumped by 95 bps to 1050.0% in 2023, then tumbled by 3062 bps to 33200.0% in 2024, then jumped by 100 bps to 49.32% in 2025.
• Per Business Quant data, the three most recent FCF Margin figures were 49.32% in Q4 2025, 461.67% in Q3 2025, and 144.44% in Q2 2025.